Brief: Silo Pharma’S SPU-21 Treatment For Autoimmune Disease Awarded US Patent
21/06/2023 14:06
June 21 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA’S SPU-21 TREATMENT FOR AUTOIMMUNE DISEASE
AWARDED
U.S. PATENT
Source text for Eikon: ID:nGNXnwJ7B
Further company coverage: SILO.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement